ReviewCancers2023
Supratotal Surgical Resection for Low-Grade Glioma: A Systematic Review.
Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Influence of supratotal resection on overall survival and progression of tumor in gliomas grade 2 and 3: a systematic review and meta-analysis.Neurosurgical review · 2025Pooled it
- Article
- U-ConvNext: A Robust Approach to Glioma Segmentation in Intraoperative Ultrasound.Journal of imaging informatics in medicine · 2026Article
- Management of Adult Patients With Isocitrate Dehydrogenase-Mutant Gliomas in Australia: An Expert Position Statement From the Cooperative Trials Group for Neuro-Oncology.Asia-Pacific journal of clinical oncology · 2026Review
- Spatial tumour characteristics as an indirect marker of metabolic dysregulation: evaluation for non-invasive IDH-genotyping of glioma using hybrid [18 F]FET-PET/MRI.European journal of nuclear medicine and molecular imaging · 2026Article
- Surgical decision making in the era of supramarginal glioma resections: a current perspective and narrative review.CNS oncology · 2025Review
- Review
- Epileptogenic LGG surgery with seizure freedom purpose: Supratotal resection (ETT-SpTR) based on Electrocorticography and navigated transcranial magnetic stimulation.Acta neurochirurgica · 2025Article
- Tumor-related epilepsy in glioma: A multidisciplinary overview.Epilepsia · 2025Review
- Neuro-oncological superiority of supratotal resection in lower-grade gliomas.Neuro-oncology · 2025Article
- Pushing the boundaries of neurosurgical oncology: evaluating the superiority of supratotal resection over gross total resection in intraoperative MRI-guided glioma surgery.Neurosurgical review · 2025Article
- The determination of the boundaries and prediction the radicality of glioblastoma resection using MRI and CT perfusion.Frontiers in neurology · 2025Article
- The role of a multidisciplinary clinic for management of patients with IDH mutant gliomas.Frontiers in oncology · 2025Article
- Non-invasive prehabilitation to foster widespread fMRI cortical reorganization before brain tumor surgery: lessons from a case series.Journal of neuro-oncology · 2024Article
- A cuproptosis-related gene DLAT as a novel prognostic marker and its relevance to immune infiltration in low-grade gliomas.Heliyon · 2024Article
- Focus on current and emerging treatment options for glioma: A comprehensive review.World journal of clinical oncology · 2024Review
- Clinical characteristics and surgical outcomes of low-grade epilepsy-associated brain tumors.Therapeutic advances in neurological disorders · 2024Article
- High costs, low quality of life, reduced survival, and room for improving treatment: an analysis of burden and unmet needs in glioma.Frontiers in oncology · 2024Review
- Oncological and functional outcomes support early resection of incidental IDH-mutated glioma.Acta neurochirurgica · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Low-grade gliomas (LGGs) are optimally treated with up-front maximal safe surgical resection, typically defined as maximizing the extent of tumor resection while minimizing neurologic risks of surgery. Supratotal resection of LGG may improve outcomes beyond gross total resection by removing tumor cells invading beyond the tumor border as defined on MRI. However, the evidence regarding supratotal resection of LGG, in terms of impact on clinical outcomes, such as overall survival and neurologic morbidities, remains unclear. Authors independently searched the PubMed, Medline, Ovid, CENTRAL (Cochrane Central Register of Controlled Trials), and Google Scholar databases for studies evaluating overall survival, time to progression, seizure outcomes, and postoperative neurologic and medical complications of supratotal resection/FLAIRectomy of WHO-defined LGGs. Papers in languages other than English, lacking full-text availability, evaluating supratotal resection of WHO-defined high-grade gliomas only, and nonhuman studies were excluded. After literature search, reference screening, and initial exclusions, 65 studies were screened for relevancy, of which 23 were evaluated via full-text review, and 10 were ultimately included in the final evidence review. Studies were evaluated for quality using the MINORS criteria. After data extraction, a total of 1301 LGG patients were included in the analysis, with 377 (29.0%) undergoing supratotal resection. The main measured outcomes were extent of resection, pre- and postoperative neurological deficits, seizure control, adjuvant treatment, neuropsychological outcomes, ability to return to work, progression-free survival, and overall survival. Overall, low- to moderate-quality evidence was supportive of aggressive, functional boundary-based resection of LGGs due to improvements in progression-free survival and seizure control. The published literature provides a moderate amount of low-quality evidence supporting supratotal surgical resection along functional boundaries for low-grade glioma. Among patients included in this analysis, the occurrence of postoperative neurological deficits was low, and nearly all patients recovered within 3 to 6 months after surgery. Notably, the surgical centers represented in this analysis have significant experience in glioma surgery in general, and supratotal resection specifically. In this setting, supratotal surgical resection along functional boundaries appears to be appropriate for both symptomatic and asymptomatic low-grade glioma patients. Larger clinical studies are needed to better define the role of supratotal resection in LGG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.